Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders

• Published in: Pharmacology & therapeutics (Oxford) 2016-10, Vol.166, p.106-122
• Main Authors: Ganai, Shabir Ahmad, Banday, Shahid, Farooq, Zeenat, Altaf, Mohammad
• Format: Article
• Language: English
• Subjects: Acetylation; Alzheimer Disease - drug therapy; Alzheimer Disease - physiopathology; Amyotrophic Lateral Sclerosis - drug therapy; Amyotrophic Lateral Sclerosis - physiopathology; Animals; Histone Acetyltransferases - metabolism; Histone Deacetylase Inhibitors - pharmacology; Histone Deacetylase Inhibitors - therapeutic use; Histone Deacetylases - metabolism; Humans; Huntington Disease - drug therapy; Huntington Disease - physiopathology; Neurodegenerative Diseases - drug therapy; Neurodegenerative Diseases - physiopathology; p300-CBP Transcription Factors - metabolism; Parkinson Disease - drug therapy; Parkinson Disease - physiopathology
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2016.07.001

Epigenetic mechanisms are emerging as a fundamental regulatory switch in neuronal function. Acetylation homeostasis governed by the antagonistic activities of HATs and HDACs plays a critical role in neuronal gene activity. It is now becoming increasingly clear that several neurodevelopmental, neurodegenerative, and neuropsychiatric disorders are caused by aberrant changes in chromatin acetylation. Several HATs have been shown to be vital for neuronal processes such as synaptic plasticity and memory formation. Thus not surprisingly, dysregulation of such HATs has been implicated in the pathogenesis of several neurodegenerative diseases including Huntington's disease (HD) and Alzheimer's disease (AD). The current therapeutic strategy involves the use of small-molecule histone deacetylase inhibitors to compensate the acetylation deficits arising due to loss of HAT activity. Despite the promising therapeutic effects, the lack of isoform (target) specificity of HDACi raises concerns regarding their applicability. Mounting evidences about the role of HATs in neuronal survival, learning and memory has triggered a new wave of modulating specific HATs as a novel therapeutic option to tackle neurodegenerative diseases. In this review we focus on different HAT families and the critical roles they play in neural development and how the altered acetylation homeostasis culminates in neurodegeneration. Further, we describe the HDACi-based therapeutic approach and its flip side in overcoming neurodegenerative diseases. Furthermore, we discuss the therapeutic potential of HAT modulators in reinstating acetylation homeostasis to ameliorate neurodegenerative disorders.